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Table 7

Table 4
Analytic cancer cases1
Cases in the cancer registry
Cases in follow-up
Hospital discharges
Inpatient cancer discharges
Total cancer patient days
Average length of stay
(cancer patient)
Radiation therapy patients
treated

2004
1,401
11,506*
6,483*
24,306
1,432
7,234
5.1

2005
1,376
12,883
7,306
24,932
1,347
6,620
4.9

2006
1,456
14,339
8,481
25,763
1,589
7,627
4.8

791

829

775

(505 SCH2)
(241 Alex3)

(576 SCH2) (533SCH2)
(253 Alex3) (242 Alex3)

Hospice patients (cancer)
105
# of cases presented at
236**
cancer/breast conference
Average # of physicians
10
attending weekly cancer conference

129
224**

136
194**

9

7
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1Cases diagnosed and/or received their first course of therapy
at St. Cloud Hospital/Coborn Cancer Center/CentraCare Radiation
Oncology at Douglas County Hospital, Alexandria.
2 SCH is St. Cloud Hospital.
3Alex is CentraCare Radiation Oncology at Douglas County Hospital,
Alexandria.
*In 2004, the cancer registry changed its reference date from
1986 to 1994.
**Breast Conference cases and attendance are included in this figure
starting in 2003.
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AJCC STAGE: ANALYTIC CASES
ABSTRACTED IN 2006
(Total cases and top four cancer sites)

Table 5
Site
In Situ I
II
All Cases
90 283 393
Prostate
0
0 221
Breast
34 105 69
Lung/Bronchus 0
22 10
Colon/Rectum 18 21 26

III
184
20
25
43
41

IV
207
9
10
85
17

Unk NA**Total
119 180 1,456
7
0
257
9
1
253
14
5
179
11
5
139

**NA (Not Applicable) refers to cancers that do not have
an AJCC staging scheme.
(AJCC=American Joint Commission on Cancer)

SITE INCIDENCE OF TOP FOUR CANCER SITES
Table 6
(Compared to total number of cancers diagnosed)

Site
St. Cloud Hospital
Prostate
18%
Breast
17%
Lung
12%
Colon/Rectum 10%

Minnesota*
18%
13%
11%
10%

Nationwide*
17%
15%
12%
11%

*Minnesota and nationwide statistics are taken from
the ACS Facts/Figures 2006
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Oral Cavity
Tongue
Oropharynx, Hypopharynx
Other Oral Cavity
Digestive System
Esophagus
Stomach
Colon
Rectum, Rectosigmoid
Anus/Anal Canal
Liver & Bile Ducts
Pancreas
Other Digestive
Respiratory System
Larynx
Lung/Bronchus
Other Respiratory
Hematopoietic/Lymphoid
Leukemia
Multiple Myeloma
Other Hemotopoietic
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Bone
Connective/Soft Tissue
Skin
Melanoma
Other Skin
Breast
Female Genital
Cervix Uteri
Corpus Uteri
Ovary
Other Female Genital
Male Genital
Prostate
Testis
Other Male Genital
Urinary
Bladder
Kidney/Renal
Other
Brain and CNS
Brain (Benign)
Brain (Malignant)
Other Brain and CNS
Endocrine
Thyroid
Other Endocrine
Unknown Primary
Other/Ill-Defined
Total

2004 2005 2006
25
27
26
5
10
5
3
0
2
17
17
19
177 203 215
12
22
17
8
6
11
71
98
107
43
35
32
3
3
0
6
6
3
22
18
27
12
15
18
219 203 196
14
9
10
200
193 179
5
1
7
118 125 148
20
34
35
22
10
21
13
12
22
9
6
12
54
63
58
0
1
4
2
5
5
32
29
29
30
27
26
2
2
3
266 266 253
46
45
51
3
3
2
25
33
24
14
7
14
4
2
1
289 231 265
275
214 257
13
14
6
1
3
2
110 129 150
52
65
70
53
61
75
5
3
5
46
38
36
2
0
0
23
17
20
21
21
16
43
55
48
32
46
41
11
9
7
20
16
21
8
3
9
1,401 1,376 1,456
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The Cancer Registry at Coborn
Cancer Center has provided
support for physicians serving
cancer patients in the Central
Minnesota area for more than 21
years. The registry’s work allows
health professionals to better
understand and develop effective
cancer treatment, prevention and
control programs.
In 2006, 1,456 patients were
entered into the registry database
(See table 4). This is the largest
number of patients accessioned
into the database since initiation
of the cancer registry in 1986.
The American Cancer Society
Cancer Facts and Figures 2006
reports the four most commonly
diagnosed cancers as breast,
prostate, lung, and colon/rectum
(See table 5). This is in accordance
with findings by the Coborn
Cancer Center registry.

Breast cancer is the most
commonly diagnosed cancer for
women in the United States;
however, we experienced a slight
decrease from 266 in 2005 to 253 in
2006. The majority of these
patients (82%) were diagnosed at
an early stage (0 to II). We are
fortunate to have a dedicated
breast center to promote
awareness and improve care for
breast cancer patients throughout
Central Minnesota.
Prostate cancer remains the most
common cancer diagnosis among
men. The registry reports that 86%
of prostate cancer patients were
diagnosed with early stage (I to II)
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cancer in 2006. With the help and
support of dedicated urology and
radiation specialists, this
community provides the most upto-date diagnostic and treatment
modalities for prostate cancer.
Lung cancer continues to account
for a significant amount of cases
entered into the registry database
annually. The number of lung
cases accessioned during 2006 was
179; slightly lower than the 193
cases in 2005 (See table 7). The
majority of lung cancer patients
(72%) were diagnosed at a late
stage (III or IV), which is
consistent with national statistics.
Late stage at diagnosis plays a
significant role in the poor survival
outcomes for this disease. This, in
part, reflects the fact that no
effective screening methods are
available to diagnose lung cancer
early. Recognizing the importance
of community education, Coborn
Cancer Center added a lung
cancer care coordinator to
coordinate multidisciplinary care
and educate on preventative
health behaviors such as tobacco
cessation.
Colorectal cancer continues to be
one of the top four cancers
diagnosed in Central Minnesota.
There were 139 cases accessioned
into our registry in 2006. Forty-one
percent of these cases were
diagnosed as early stage (0 to II).
Although there are currently more
treatment options than ever
before, the overall survival
depends upon early detection.
Coborn Cancer Center helped

Harold Windschitl, M.D.
Hematology Oncology
educate the public by sponsoring
the Super Colon. More than 3,000
people toured a life-size colon and
learned early warning signs. After
the event, several physicians
reported having patients present
with colorectal cancer symptoms.
A noticeable trend has been the
increasing numbers of bladder
and kidney cancers accessioned
over the past four years. This may,
in part, be due to the increased
number of urology physicians in
this area who are providing more
outreach services to other
facilities’ patients.
Early detection and treatment
continues to be a high priority
with any type of cancer. It is
imperative for long-term survival.
The activities and information the
registry provides is essential for
programmatic and administrative
planning, researching, and
monitoring of outcomes for
Coborn Cancer Center patients.
For more information e-mail
cancercenter@centracare.com or
visit www.centracare.com.
8/2007 1,400
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CHAIRPERSON’S REPORT
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Persons who receive a diagnosis of cancer need
the best care possible. Coborn Cancer Center
works with St. Cloud Hospital’s Cancer Care
Center Board to ensure comprehensive services
of the highest quality exist for cancer prevention,
diagnosis, treatment and aftercare.

E P O R T

Cancer treatment continues to be focused
around surgery, chemotherapy and radiation.
Central Minnesotans are fortunate to have a
comprehensive community cancer center that
attracts board-certified and specialty trained
physicians. Cancer-related physician specialties
on our team include:
• Surgery - general, colorectal, gynecology,
neurosurgery, oral, maxillofacial,
otorhinolarynogology, orthopedic, plastic
and reconstructive, and urology
• Medical oncology and hematology
• Radiation oncology
• Diagnostic and interventional radiology
• Pathology
• Gastroenterology
• Pulmonology
• Genetics

A N C E R
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Physicians and other cancer care providers meet
weekly to discuss the optimal treatments for
patients diagnosed and treated in Coborn Cancer
Center. These conferences are one example of
how we ensure our patients a strong
multidisciplinary approach to care.

C

Thanks to our dedicated clinicians and staff it
has been a pivotal year of expansion and new
programming. We want to highlight a few
initiatives from the last year.

Radiation Oncology
Coborn Cancer Center offers the latest
technology for cancer care. Our physicians use
an Electa Synergy S Linear Accelerator to offer
cancer patients the most recent advances in
radiation therapy including Intensity Modulated
Radiation Therapy (IMRT), Image Guided
Radiation Therapy (IGRT), and Stereotactic
Radiosurgery (SRS).
IGRT involves the use of imaging tools to
precisely localize the area being treated and to
verify daily how the treatment is delivered to the
tumor. IGRT tools and techniques help clinicians
and staff adapt radiation plans to deal with tumor
motion due to respiration. We can then deliver
higher doses of radiation to the tumor while
minimizing radiation to the normal surrounding
area.
A specialized team works together to deliver
SRS for the treatment of brain tumors. SRS
is the very precise delivery of radiation to a brain
tumor while sparing the normal surrounding
2

Table 1
brain tissue. Information from CT scans and MRIs
are transferred to the treatment planning
computer to create a 3D image of the tumor. Our
physicians then develop a complex plan to
deliver a targeted high dose of radiation, while
limiting radiation to nearby brain tissue. The
procedure is done at Coborn Cancer Center
without the need for an invasive surgical
procedure or an inpatient hospitalization.
We have also expanded the radiation implant
or brachytherapy service with the introduction
of High Dose Rate Remote After-loading Implant
Therapy (HDR). This therapy delivers radiation on
an outpatient basis in the comfort of a
specialized brachytherapy suite. The physician,
through the use of a robot, places the radioactive
source into an applicator at the location of the
tumor. This treatment is delivered in a matter of
minutes. HDR is used to treat many different
types of tumors. Breast cancer can be treated
with HDR using the Mammosite Catheter System.
With the Mammosite technique, eligible patients
receive treatment in only five days versus a sixweek standard course of treatment.

Medical Oncology
Advances in the medical treatment of cancer are
happening at an accelerated rate. The approval of
more and better medications is offering
improved outcomes for many patients.
Within the past year medical oncologists have
been able to offer newly FDA released
chemotherapy, biologic and targeted therapies
for advanced renal cell cancer, metastatic
colorectal cancer, breast cancer, lung cancer,
multiple myeloma and myelodysplastic
syndrome.
Additionally some existing chemotherapy agents
have been approved for delivery in new ways.
Coborn Cancer Center clinicians have begun an
intraperitoneal chemotherapy program for
eligible ovarian cancer patients.

Lung Cancer Care Coordination
Persons facing a new diagnosis of lung cancer
quickly find themselves facing a tremendous
number of critical and often times frightening
decisions. Coborn Cancer Center diagnoses
approximately four new respiratory cancers every
week. In January 2007 Debbie Corrigan, RN
joined us as the lung cancer care coordinator
to help these patients navigate the complex
diagnosis and treatment journey.

Cancer Survivorship
The ability to be a long-term cancer survivor
today is more the norm than an exception.
Approximately 3.5 % of the population is a
survivor of cancer, accounting for about 22,000
people in Central Minnesota. To enhance

support for these survivors Sandy Johnson, RN,
AOCNS, and Jo Zwilling, RN, MBA, Cancer Center
Director, were accepted to participate in the National
Cancer Institutes Cancer Survivorship Research
Program and will spearhead innovative survivorship
programming. In April 2007 Mary Navara, RN, MPH,
joined us as the survivorship network coordinator.

Cancer Research
Coborn Cancer Center has a longstanding
commitment to cancer clinical research. The research
department currently oversees 130 prevention,
treatment, and control studies. We offer patients
participation in national clinical chemotherapy and
radiation research trials through North Central Cancer
Treatment group (NCCTG) and Radiation Therapy
Oncology Group (RTOG). Through these
multidisciplinary cooperative organizations, people in
Central Minnesota have access to the newest cancer
modalities and drugs.

Quality Outcomes

HEMATOPOIETIC NEOPLASMS: 2002 TO 2006

At Coborn Cancer Center we monitor indicators and
outcomes, and compare our results to national data.
Our five-year survival rates often are better than
national survival rates. Multidisciplinary clinical teams
are in place to select and monitor outcomes for breast,
prostate, lung and head/neck cancers. Visit our Web
site for outcome measures which may be of particular
interest to you.

HISTOLOGY

In conclusion
We are proud to offer you the paramount in
technology and patient experience. We invite you
to visit us or call us for a tour. Thank you to the many
physicians and staff who work every day to make this
a premier cancer center. Thanks especially to our
patients. We are grateful for your trust.
Sincerely,

The most common plasma cell
tumors are plasmacytomas and
multiple myelomas. Plasmacytomas
are considered a localized disease.
Most plasmacytomas progress to
multiple myeloma, which is systemic
disease.
Multiple myeloma accounted for an
estimated 16,570 new cancer cases in
the United States in 2006 with an
estimated 11,310 deaths.

Treatment for multiple
myeloma may include
chemotherapy, biological
agents and stem cell transplant.
At St. Cloud Hospital, 61 out of
68 patients were treated with
chemotherapy and/or
biological agents such as
thalidomide, lenalidomide and
bortezomib therapy. Of the
seven patients who did not
receive systemic therapy, three were
diagnosed with “smoldering
myeloma” and did not require
treatment, three had other medical
conditions, which precluded
treatment, and one declined therapy.
Six patients were documented in the
registry as receiving stem cell
transplants at other facilities.
Survival rates for multiple myeloma
patients diagnosed and/or treated at
Coborn Cancer Center compare
favorably with national statistics. See
Table 2.
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1

0

1

2

2

6

Multiple myeloma

11

9

21

8

19

68

Mast cell leukemia

0

0

1

0

0

1

Waldenstrom’s
macroglobulinemia

0

1

0

2

1

4

1

3

2

0

1

7

Chronic lymphocytic leukemia 5

12

5

12

7

41

T-cell large granular

0

1

1

2

1

5

10

10

8

14

12

54

LEUKEMIAS
Lymphoid Leukemias
Acute lymphoid leukemias

Other Leukemia

Nicholas F. Reuter, MD, FACP
Cancer Center Medical Director
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Plasma Cell Tumors

Plasmacytoma NOS

Acute myeloid leukemias

We have just completed a two-year, nearly 20,000
Jo Zwilling, RN, MBA
additional square foot expansion. The expansion
Cancer Center Director
has brought together technical advances in a
compassionate and healing environment. New features
include a fireplace, fish aquarium, lighted wall, visual
therapy murals and enhanced patient and family
resource center.

H

PLASMA CELL TUMORS

Myeloid Leukemias

Expansion of Coborn Cancer Center

Hematopoietic neoplasms arise in
organs and tissues that are involved
in the production of blood; mainly,
bone marrow, spleen, tonsils and
lymph nodes. This report will focus
on the neoplasms arising primarily in
the bone marrow. These “bone
marrow tumors” are not common, as
shown in Table 1; they comprised
about 5% of the cases seen at
Coborn Cancer Center in 2006. Many
patients with these diseases can live
for a long time. The statistics given in
this report only reflect newly
diagnosed patients.

2002 2003 2004 2005 2006 TOTAL

Hani Al-Khatib, M.D.
Hematology Oncology
Table 2
5 YR RELATIVE SURVIVAL RATE:
MULTIPLE MYELOMA
1996 TO 2003
SCH

SEER*

36.2

33.6

Leukemia
Leukemia is a disease in which the
blood forming cells do not
reproduce in a normal manner. In
acute leukemia, the blood cells
remain in an immature state, but
reproduce quickly.

Hairy cell leukemia

1

2

2

0

2

7

Chronic myelomonocytic
leukemia

2

1

0

1

4

8

CHRONIC MYELOPROLIFERATIVE
DISORDERS

11

8

8

5

11

43

MYELODYSPLASTIC SYNDROME

5

10

6

10

18

49

TOTALS

47

57

55

56

78

293

Acute myeloid leukemia (AML)
makes up the largest percentage
of acute leukemias diagnosed
and/or treated at St. Cloud
Hospital. As the population ages,
the incidence of AML, along with
myelodysplasia, appears to be
rising. Treatment for AML consists
of chemotherapy. Thirty-nine of
the 54 AML cases seen at St. Cloud
Hospital were treated with
chemotherapy. Of the 15 patients
that did not receive treatment, six
declined treatment and nine did
not receive treatment due to comorbidities or patient condition.
Five AML patients were
documented in the registry as
receiving stem cell transplants at
other facilities. Survival rates for
the AML patients diagnosed
and/or treated at Coborn Cancer
Center compare favorably with
national statistics. See Table 3.

the most common leukemia in the
United States. It usually occurs in
older adults. Many patients do not
need treatment.

In chronic leukemias, the blood
cells eventually mature, but are
not normal. Chronic lymphocytic
leukemia (CLL) is the most
common chronic leukemia seen at
Coborn Cancer Center. It also is

Chronic myeloproliferative
disorders are diseases in which
one or more blood stem cells
overproduce blood cells. Of the 43
patients newly diagnosed with a

Chronic Myeloproliferative
Disorders and Myelodysplastic
Syndrome
In 2001, the World Health
Organization reclassified chronic
myeloproliferative disorder and
myelodysplastic syndrome as
malignant neoplasms and cancer
registries began to collect data on
these cases.

Table 3
5 YR RELATIVE SURVIVAL RATE
ACUTE MYELOID LEUKEMIA
1996 TO 2003
SCH

SEER*

30.5 %

20.7 %

myeloproliferative disorder and
seen at Coborn Cancer Center
from 2002 to 2006, nine had
chronic myelogenous leukemia,
nine had polycythemia vera, 17
had essential thrombocythemia,
seven had chronic
myeloproliferative disorders, NOS,
and one had myelofibrosis.
Chronic myelogenous leukemia is
a special entity with a specific
treatment. Most patients are
diagnosed with a genetic
abnormality called the
Philadelphia chromosome. In
these patients, too many white
blood cells are produced. It is
treated with molecular targeted
drugs such as imatinib and
dasatinib.
Myelodysplastic syndromes (MDS)
are characterized by a disruption
in production of blood cells
resulting in low levels of mature
cells. There are several subtypes of
MDS making management of
these patients complex. About
30% of MDS patients will develop
acute leukemia. There has been a
significant increase in the number
of MDS cases seen at Coborn
Cancer Center. This may be
related to the aging population.
Recent FDA approval for new
drugs to treat specific subtypes of
MDS include lenalidomide,
azacytidine and decitabine. Of the
18 patients seen at Coborn Cancer
Center in 2006, nine were treated
with lenalidomide or azacytidine.
It is hoped, with new treatment
options available, overall
prognosis for these patients will
improve.
The medical management of
patients with hematological
disorders remains a challenging
endeavor. It does appear that the
incidence of these diagnoses will
continue to increase in our
community. We look forward to
the future as new treatment
options are developed and
approved that will add quality of
life and improve prognosis for
these patients.

*SEER: Statistics are from the National
Cancer Institute’s Surveillance,
Epidemiology & End Results Program
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